Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016

SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets.  The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.

Conference Call & Webcast InformationWhen: August 8, 2016, 4:30 p.m. ETDial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)Conference ID: Arena Pharmaceuticals Second Quarter 2016 Conference Call

Please join the conference call at least 10 minutes early to register.

You can access the live webcast under the investor relations section of Arena's website at: www.arenapharma.com.

A replay of the conference call will be archived under the investor relations section of Arena's website at www.arenapharm.com for 30 days shortly after the call.

About Arena PharmaceuticalsWe are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.  We have three primary proprietary clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis; ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH); and, APD371 which has completed Phase 1 testing.  Additionally, we have collaborations with four pharmaceutical companies: Eisai Ltd. and Eisai Inc. (commercial stage); Axovant Sciences Ltd. (Phase 2 candidate); Ildong Pharmaceuticals Co., Ltd (Phase 1 candidate); and, Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's focus, plans and strategy; and the advancement and potential of Arena's clinical programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that the cost and other negative effects related to the reduction of Arena's workforce may be greater than anticipated; the risk that Arena may not realize the benefits expected from the workforce reduction or other cost control measures; risks related to developing and commercializing drugs; the risk that we may need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; cash and revenues generated from BELVIQ, including the impact of competition; the risk that Arena's revenues are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and lorcaserin may not be approved for marketing in a different formulation or in any other territory; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's and third parties' intellectual property rights; the timing, success and cost of Arena's research and development and related strategy and decisions; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact:Kevin R. Lind, Chief Financial Officer[email protected]858.453.7200 x1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-second-quarter-2016-financial-results-and-provide-corporate-update-on-monday-august-8-2016-300307030.html

SOURCE Arena Pharmaceuticals, Inc.